IL2RG and breast carcinoma: Besides, HECTD3, PSMB10, UBD, UBE2C, and UBE2S involved in the ubiquitin proteasome pathway, as well as CCL2, CCR1, CXCL10, CXCL11, and IL2RG implicated in the cytokine–cytokine receptor interaction pathway, might be used for evaluating the efficacy of neoadjuvant chemotherapy in breast cancer.